Navigation Links
Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
Date:2/22/2008

ative:

Non-cash

compensation 1,893 569 7,086 8,408

Other selling,

general and

administrative 2,643 2,564 9,919 9,110

Total selling,

general and

administrative 4,536 3,133 17,005 17,518

TOTAL OPERATING EXPENSES 31,027 20,098 95,630 80,691

OPERATING LOSS (30,122) (19,997) (94,581) (80,157)

OTHER INCOME:

Interest and other

income, net 897 1,650 4,555 6,393

NET LOSS BEFORE INCOME

TAXES (29,225) (18,347) (90,026) (73,764)

Income taxes 36 -- 36 --

NET LOSS $(29,261) $(18,347) $(90,062) $(73,764)

NET LOSS PER COMMON SHARE

Basic and diluted $(0.67) $(0.42) $(2.07) $(1.76)

SHARES USED IN COMPUTING

NET LOSS PER COMMON SHARE

Basic and diluted 43,651,587 43,241,090 43,583,950 41,919,741

Balance Sheet Information:

December 31, December 31,

2007 2006*

(unaudited)

Cash, cash equivalents, interest

receivable and investment securities $64,682 $125,610

Total assets 81,061 140,313

Accumulated deficit (278,274) (188,212)

Stockholders' equity 44,422 123,821

* Condensed from audited financial statements.


'/>"/>
SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
2. Keryx Biopharmaceuticals Announces Additions to Management Team
3. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
4. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
5. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
6. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
7. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
8. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
9. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
10. Webcast Alert: Transgenomic Inc. Announces Fourth Quarter 2007 Earnings Release Conference Call Webcast
11. Genta Announces Senior Management Changes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... , July 28, 2015 CSL Behring ... Administration has accepted for review the company,s Biologics License ... single-chain (rVIII-SingleChain) for the treatment of hemophilia A. In ... Hemophilia A is a ... VIII; nearly all affected patients are male. People with ...
(Date:7/28/2015)... , July 28, 2015  Faced with ... that are palliative rather than symptomatic, the global ... few existing therapies capable of curing or significantly ... are starting to look towards regenerative medicine as ... a new paradigm in human health with the ...
(Date:7/27/2015)... ... 27, 2015 , ... This is a professional and in-depth ... overview of the industry including definitions, classifications, applications and industry chain structure. The ... landscape analysis, and key regions development status. Development policies and plans are discussed ...
(Date:7/27/2015)... , July 27, 2015 Research presented at ... will expand on the studies that led to a ... diagnostic for this disease to receive approval from the ... to breaking Ebola,s grip on West Africa ... and enabling healthcare workers to isolate and treat these ...
Breaking Biology Technology:U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 2U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 3Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 2Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 3Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 4Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 52015 Biophotonics Market Global Research 22015 Biophotonics Market Global Research 3Rapid Ebola Test Could Play Key Role in Efforts to End Lingering Outbreak 2Rapid Ebola Test Could Play Key Role in Efforts to End Lingering Outbreak 3
... is a black box. A complex circuitry of neurons ... of a computer chip. But while computer processors are ... neural circuits are impenetrable masses. Think tumbleweed. Researchers ... a technique for unraveling these masses. Through a combination ...
... WEST LAFAYETTE, Ind. - Researchers are developing a technology ... and efficient by using a new manufacturing method that ... help to overcome two major obstacles that hinder widespread ... costs and increase the efficiency of converting sunlight into ...
... computer memory that can retain stored information even ... Cornell University researchers have discovered a new way of ... a very fast oscilloscope, researchers led by Dan Ralph, ... the J.E. Sweet Professor of Applied and Engineering Physics, ...
Cached Biology Technology:Web-crawling the brain 2Web-crawling the brain 3Ultrafast laser 'scribing' technique to cut cost, hike efficiency of solar cells 2Physicists measure current-induced torque in nonvolatile magnetic memory devices 2
(Date:7/20/2015)... 2015  Acuity Market Intelligence,s latest research "The ... Commerce and Privacy" forecasts that between 2014 and ... be downloaded to smart mobile devices by 2.2 ... is projected to generate more than $67.9 billion ... forecast period.    "Biometrics is at ...
(Date:7/9/2015)... 2015 Research and ... the "Biometrics for Banking; Market & Technology ... to their offering. The adoption for ... growth and the forecast is that by 2020 ... companies involved in delivering biometric systems to the ...
(Date:7/8/2015)... LAKES , N.J. and NEW YORK ... Company) and Guidepoint today announced BD ... start-up healthcare companies with free access to Guidepoint,s expert ... several start-ups that are developing cutting-edge technologies to improve ... a dedicated Guidepoint research manager, each start-up entrepreneur will ...
Breaking Biology News(10 mins):Biometrics on Smart Mobile Devices to Redefine Digital Identity with 12.9 Billion Biometric App Downloads between 2014 and 2020 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3
... 12, 2011 UC Irvine researchers have found a ... virulent flu strains that resist current antiviral drugs. ... Bush created a method to predict how pocket structures ... can be identified as these proteins evolve, allowing for ...
... 2011A history of psychiatric illness such as depression or ... other risk factors, are strongly predictive of post-TBI psychiatric ... of Neurotrauma , a peer-reviewed journal published by Mary ... at www.liebertpub.com/neu In addition to a ...
... FL. Research to be presented at the upcoming ... Ingestive Behavior (SSIB), the foremost society for research into ... people can become dependent on highly palatable foods and ... the behaviors we observe in drug addicts and those ...
Cached Biology News:UCI study points to new means of overcoming antiviral resistance in influenza 2Evidence for 'food addiction' in humans 2
...
BD BioCoat Collagen IV 35 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of mouse collagen type IV....
... primers are designed for sequencing inserts cloned ... T7, or T3 RNA polymerase promoters, or ... supplied at a concentration of 0.1 µg/µl ... in DNA sequencing reactions using SequiTherm™ EXCEL™ ...
BD BioCoat Matrigel Matrix 35 mm Culture Dishes Coating : BD MatrigelTM Basement Membrane Matrix ,Surface : ECM/attachment factors ,Surface area : 9.6 cm2 ,Dim nominal : 35 mm x 10 mm ,Vo...
Biology Products: